Cobra Biologics and KAHR Medical Limited will continue their partnership. The move will allow Cobra to advance both KAHR-101 and KAHR -102 for future preclinical and clinical testing using its maxXpress service.
MaxXpress enable rapid clone selection and production by combining UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team. Cobra Biologics will also carry out the process development and scale up for GMP production of both KAHR-101 and KAHR-102.
Peter Coleman, chief executive officer at Cobra Biologics, said, “I am delighted to extend our partnership with KAHR, which has been strengthened over a number of years due to the excellent working relationship between both technical teams and we look forward to its continuation.”
Dr. Noam Shani, chief executive officer of KAHR Medical, added, “It has been a pleasure working with Cobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of both KAHR-101 and KAHR-102.”